Skip to main content

Advertisement

SpringerLink
Log in

PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 04 May 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05210-9.

  2. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59(2):230–7. https://doi.org/10.2967/jnumed.117.201749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pereira Mestre R, Treglia G, Ferrari M, Pascale M, Mazzara C, Azinwi NC, et al. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: a meta-analysis. Eur J Clin Investig. 2019;49(3):e13063. https://doi.org/10.1111/eci.13063.

    Article  CAS  Google Scholar 

  4. Triviño-Ibáñez EM, Puche-Sanz I, Gómez-Río M, Cózar Olmo JM, Llamas-Elvira JM, Rodríguez-Fernández A. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy. Med Clin (Barc). 2019;153(2):56–62. English, Spanish. https://doi.org/10.1016/j.medcli.2018.11.018.

    Article  Google Scholar 

  5. Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):9–15. https://doi.org/10.1007/s00259-019-04529-8.

    Article  CAS  PubMed  Google Scholar 

  6. Evangelista L, Bonavina MG, Bombardieri E. Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer. Nucl Med Biol. 2017;50:47–9. https://doi.org/10.1016/j.nucmedbio.2017.04.001.

    Article  CAS  PubMed  Google Scholar 

  7. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403–17. https://doi.org/10.1016/j.eururo.2019.01.049.

    Article  PubMed  Google Scholar 

  8. Zattoni F, Ravelli I, Rensi M, Capobianco D, Borsatti E, Baresic T, et al. 10-year clinical experience with 18F-choline PET/CT: an Italian multicenter retrospective assessment of 3343 patients. Clin Nucl Med. 2020;45(8):594–603. https://doi.org/10.1097/RLU.0000000000003125.

    Article  PubMed  Google Scholar 

  9. Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D’Andrea D, Berndl F, et al. Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate. 2020;80(1):74–82. https://doi.org/10.1002/pros.23919.

    Article  CAS  PubMed  Google Scholar 

  10. Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R, Borghesi M, et al. (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging. 2016;43(1):84–91. https://doi.org/10.1007/s00259-015-3177-4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy

    Laura Evangelista

  2. Nuclear Medicine Unit, Fondazione Istituto G.Giglio, Cefalù, Italy

    Pierpaolo Alongi

Authors
  1. Laura Evangelista
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierpaolo Alongi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura Evangelista.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was not required for the present study.

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Oncology - Genitourinary

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Evangelista, L., Alongi, P. PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. Eur J Nucl Med Mol Imaging 48, 1709–1711 (2021). https://doi.org/10.1007/s00259-021-05295-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-021-05295-2

Search

Navigation